Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma
Crossref DOI link: https://doi.org/10.1038/onc.2017.122
Published Online: 2017-05-01
Published Print: 2017-08-31
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Dai, L
Lin, Z
Qiao, J
Chen, Y
Flemington, E K
Qin, Z
Text and Data Mining valid from 2017-05-01
Version of Record valid from 2017-05-01
Article History
Received: 23 January 2017
Revised: 16 March 2017
Accepted: 24 March 2017
First Online: 1 May 2017
Competing interests
: The authors declare no conflict of interest.